<HashMap><database>biostudies-literature</database><scores><citationCount>0</citationCount><reanalysisCount>0</reanalysisCount><viewCount>48</viewCount><searchCount>0</searchCount></scores><additional><submitter>Dumesic DA</submitter><funding>National Center for Advancing Translational Sciences</funding><funding>Eunice Kennedy Shriver National Institute of Child Health and Human Development</funding><funding>NICHD NIH HHS</funding><funding>NCATS NIH HHS</funding><funding>Endocrine Technologies Support Core</funding><funding>National Institutes of Health</funding><funding>NIH HHS</funding><pagination>bvab158</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8513761</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>5(11)</volume><pubmed_abstract>&lt;h4>Context&lt;/h4>Increased aldo-keto reductase 1C3 (AKR1C3)-mediated conversion of androstenedione (A4) to testosterone (T) promotes lipid storage in subcutaneous (SC) abdominal adipose in overweight/obese polycystic ovary syndrome (PCOS) women.&lt;h4>Objective&lt;/h4>This work examines whether an elevated serum T/A4 ratio, as a marker of enhanced AKR1C3 activity in SC abdominal adipose, predicts metabolic function in normal-weight PCOS women.&lt;h4>Methods&lt;/h4>This prospective cohort study took place in an academic center and comprised 19 normal-weight PCOS women and 21 age- and body mass index-matched controls. Interventions included circulating hormone/metabolic determinations, intravenous glucose tolerance testing, total body dual-energy x-ray absorptiometry, and SC abdominal fat biopsy. Serum T/A4 ratios, hormone/metabolic measures, and &lt;i>AKR1C3&lt;/i> expression of adipocytes matured in vitro were compared between female types; serum T/A4 ratios were correlated with serum lipids, adipose insulin resistance (adipose-IR), homeostatic model assessment of insulin resistance (HOMA-IR) and insulin sensitivity (Si).&lt;h4>Results&lt;/h4>Increased serum T/A4 ratios (&lt;i>P&lt;/i> = .040) and log adipose-IR values (&lt;i>P&lt;/i> = .002) in PCOS women vs controls were accompanied by &lt;i>AKR1C3&lt;/i> messenger RNA overexpression of PCOS adipocytes matured in vitro (&lt;i>P&lt;/i> = .016). Serum T/A4 ratios in PCOS women, but not controls, negatively correlated with log triglycerides (TGs: R = -0.65, &lt;i>P&lt;/i> = .002) and the TG index (R&lt;i> &lt;/i>= -0.57, &lt;i>P&lt;/i> = .011). Adjusting for serum free T, serum T/A4 ratios in PCOS women remained negatively correlated with log TG (R = -0.57, &lt;i>P&lt;/i> = .013) and TG index (R = -0.50, &lt;i>P&lt;/i> = .036), respectively, without significant relationships with other metabolic measures.&lt;h4>Conclusion&lt;/h4>An elevated serum T/A4 ratio, as a marker of enhanced AKR1C3 activity in SC abdominal adipose, predicts healthy metabolic function in normal-weight PCOS women.</pubmed_abstract><journal>Journal of the Endocrine Society</journal><pubmed_title>Serum Testosterone to Androstenedione Ratio Predicts Metabolic Health in Normal-Weight Polycystic Ovary Syndrome Women.</pubmed_title><pmcid>PMC8513761</pmcid><funding_grant_id>P50 HD071836</funding_grant_id><funding_grant_id>UL1TR001881</funding_grant_id><funding_grant_id>UL1 TR001881</funding_grant_id><funding_grant_id>P51ODO11092</funding_grant_id><funding_grant_id>P50HD071836</funding_grant_id><funding_grant_id>P51 OD011092</funding_grant_id><pubmed_authors>Abbott DH</pubmed_authors><pubmed_authors>Chazenbalk GD</pubmed_authors><pubmed_authors>Lu G</pubmed_authors><pubmed_authors>Naik R</pubmed_authors><pubmed_authors>Dumesic DA</pubmed_authors><pubmed_authors>Tulberg A</pubmed_authors><pubmed_authors>McNamara M</pubmed_authors><pubmed_authors>Grogan TR</pubmed_authors><view_count>48</view_count></additional><is_claimable>false</is_claimable><name>Serum Testosterone to Androstenedione Ratio Predicts Metabolic Health in Normal-Weight Polycystic Ovary Syndrome Women.</name><description>&lt;h4>Context&lt;/h4>Increased aldo-keto reductase 1C3 (AKR1C3)-mediated conversion of androstenedione (A4) to testosterone (T) promotes lipid storage in subcutaneous (SC) abdominal adipose in overweight/obese polycystic ovary syndrome (PCOS) women.&lt;h4>Objective&lt;/h4>This work examines whether an elevated serum T/A4 ratio, as a marker of enhanced AKR1C3 activity in SC abdominal adipose, predicts metabolic function in normal-weight PCOS women.&lt;h4>Methods&lt;/h4>This prospective cohort study took place in an academic center and comprised 19 normal-weight PCOS women and 21 age- and body mass index-matched controls. Interventions included circulating hormone/metabolic determinations, intravenous glucose tolerance testing, total body dual-energy x-ray absorptiometry, and SC abdominal fat biopsy. Serum T/A4 ratios, hormone/metabolic measures, and &lt;i>AKR1C3&lt;/i> expression of adipocytes matured in vitro were compared between female types; serum T/A4 ratios were correlated with serum lipids, adipose insulin resistance (adipose-IR), homeostatic model assessment of insulin resistance (HOMA-IR) and insulin sensitivity (Si).&lt;h4>Results&lt;/h4>Increased serum T/A4 ratios (&lt;i>P&lt;/i> = .040) and log adipose-IR values (&lt;i>P&lt;/i> = .002) in PCOS women vs controls were accompanied by &lt;i>AKR1C3&lt;/i> messenger RNA overexpression of PCOS adipocytes matured in vitro (&lt;i>P&lt;/i> = .016). Serum T/A4 ratios in PCOS women, but not controls, negatively correlated with log triglycerides (TGs: R = -0.65, &lt;i>P&lt;/i> = .002) and the TG index (R&lt;i> &lt;/i>= -0.57, &lt;i>P&lt;/i> = .011). Adjusting for serum free T, serum T/A4 ratios in PCOS women remained negatively correlated with log TG (R = -0.57, &lt;i>P&lt;/i> = .013) and TG index (R = -0.50, &lt;i>P&lt;/i> = .036), respectively, without significant relationships with other metabolic measures.&lt;h4>Conclusion&lt;/h4>An elevated serum T/A4 ratio, as a marker of enhanced AKR1C3 activity in SC abdominal adipose, predicts healthy metabolic function in normal-weight PCOS women.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Nov</publication><modification>2024-11-12T13:18:38.679Z</modification><creation>2022-02-11T12:43:29.105Z</creation></dates><accession>S-EPMC8513761</accession><cross_references><pubmed>34661039</pubmed><doi>10.1210/jendso/bvab158</doi></cross_references></HashMap>